Telix Pharmaceuticals (NASDAQ:TLX) Rating Increased to Hold at Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other equities research analysts also recently commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Tuesday. Citigroup boosted their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday. Finally, Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX opened at $10.54 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $20.00. The business’s 50-day moving average is $7.90 and its 200 day moving average is $8.73.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. On average, research analysts expect that Telix Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers raised its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at approximately $89,000. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at approximately $111,000. Vident Advisory LLC purchased a new stake in shares of Telix Pharmaceuticals in the fourth quarter worth approximately $204,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter worth approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.